SYK · Full Picture

STRYKER CORP — the full picture

Earnings window · 2026-07-10 to 2026-09-24 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

1. Revenue Performance and Mix · Revenue growth & mixPriority 77
   +19.6% revenue (realized); 3 sources (news, press_release, sec_filing); quote_verified
   Carrera Capital Advisors reduced its stake in Stryker by 68.8% in the second quarter, selling 5,260 shares and retaining 2,381 shares valued at $752,000.
2. Guidance / Outlook · Guidance & outlookPriority 75
   +8.8% revenue; 2 sources (news, press_release); 6 forward row(s); quote_verified
   STRYKER CORP narrowed full year 2026 guidance for adjusted net earnings per diluted share to a range of $14.95 to $15.10.
3. Operating Income and Margins · Operating income & profitabilityPriority 69
   +13.3% net_income (realized); 2 sources (press_release, sec_filing); structured_verified
   Three months 2026 net earnings: $1,276 million, net earnings per diluted share $3.30; three months 2025 net earnings $884 million, $2.29 per diluted share.
4. Income Tax Rate Changes · TaxPriority 57
   -8.1% margin (realized); 2 sources (press_release, sec_filing); quote_verified
   Income taxes for Q2 2026 were $288 million (vs $132 million in Q2 2025), a 118.2% increase.
5. Market Demand Trends · Demand, orders & backlogPriority 57
   3 sources (news, press_release, sec_filing); quote_verified
   Stryker's Q2 revenue only met expectations and the company missed organic sales growth forecasts, contributing to a recent 7.3% drop in the stock.
6. Net Income and EPS Performance · Operating income & profitabilityPriority 57
   +6.0% net_income (realized); 2 sources (news, press_release); quote_verified
   Earnings before income taxes for Q2 2026 were $1,564 million, a 53.9% increase versus Q2 2025 ($1,016 million).
7. Gross Margin Drivers · Gross marginPriority 55
   2 sources (news, sec_filing); quote_verified
   Three months 2026 gross profit: $4,498 million and gross margin 68.3% of net sales.
8. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 54
   +1.3% revenue; 2 sources (news, sec_filing); 6 forward row(s); structured_verified
   Change in organizational structure in first quarter 2026: creation of Ortho Tech business combining Orthopaedic Instruments with Other Orthopaedics and other portfolio realignments; Ortho Tech includes orthopaedic instruments sales of $523 and $501 for three months 2026 and 2025 respectively and Other Orthopaedics of $194 and $148 for three months 2026 and 2025 respectively.
9. Operating Cash Flow Trends · Cash flow generationPriority 47
   quote_verified
   Stryker Corporation has over $4.1 billion in free cash flow.
10. Restructuring Charges · Restructuring & impairmentPriority 47
    2 sources (press_release, sec_filing); quote_verified
    STRYKER CORP recorded structural optimization and other special charges adjustments to operating income of $95 million in Q2 2026 (Three Months 2026).
11. Supply Chain and Cybersecurity Impact · Cybersecurity & incidentsPriority 47
    2 sources (news, press_release); 1 forward row(s); quote_verified
    STRYKER CORP reported a cybersecurity incident first reported on March 11, 2026 and stated they are recovering from it.
12. Cash Flow and Capital Allocation · UnclassifiedPriority 46
    +2.1% liability (realized); 2 sources (press_release, sec_filing); structured_verified
    Cash used in investing activities six months 2026: $824 million versus $4,240 million prior year; six months 2026 included cash paid for purchases of property, plant and equipment.

Threads by pillar

Revenue & Demand Priority 85 · 6 threads

• Revenue Performance and MixPriority 77 · News, Release, Filing
• Market Demand TrendsPriority 57 · News, Release, Filing
• Procedure Volume TrendsPriority 21 · News
• Product Launch and TransitionPriority 39 · News
• Products and TechnologyPriority 34 · News
• Geographic Market CommentaryPriority 37 · Release, Filing

Costs & Margins Priority 86 · 7 threads

• Operating Income and MarginsPriority 69 · Release, Filing
• Net Income and EPS PerformancePriority 57 · News, Release
• Gross Margin DriversPriority 55 · News, Filing
• Restructuring ChargesPriority 47 · Release, Filing
• Supply Chain and Cybersecurity ImpactPriority 42 · News, Filing
• Manufacturing And CapacityPriority 34 · News
• Operating Expense TrendsPriority 35 · Filing

Capital & Balance Sheet Priority 67 · 5 threads

• Income Tax Rate ChangesPriority 57 · Release, Filing
• Operating Cash Flow TrendsPriority 47 · News
• Balance Sheet and LiquidityPriority 40 · Release, Filing
• Quarterly Dividend DeclarationPriority 34 · News
• Capital Return ProgramPriority 26 · News

Strategy & Portfolio Priority 59 · 4 threads

• Acquisition / Partnership / DivestiturePriority 54 · News, Filing
• Mako Robotics ExpansionPriority 29 · News
• Strategic InitiativesPriority 25 · News
• Licensing / Collaboration DealsPriority 19 · News

Legal, Regulatory & Policy Priority 48 · 5 threads

• Securities Fraud InvestigationPriority 35 · News
• Regulatory Approval MilestonesPriority 29 · News
• Trade Policy and TariffsPriority 33 · Filing
• Australian Non-Compete LitigationPriority 24 · News
• Patent Infringement LawsuitPriority 17 · News

Guidance & Outlook Priority 75 · 1 thread

• Guidance / OutlookPriority 75 · News, Release

Macro & Market Conditions Priority 43 · 1 thread

• Competition and Market PositionPriority 43 · News

Management & Governance Priority 47 · 1 thread

• Supply Chain and Cybersecurity ImpactPriority 47 · News, Release

Unclassified Priority 53 · 5 threads

• Cash Flow and Capital AllocationPriority 46 · Release, Filing
• Supply Chain and Cybersecurity ImpactPriority 33 · News
• Pulmonary Thrombectomy Market GrowthPriority 29 · News
• Medical Device Regulation CostsPriority 20 · Release
• Customer Product AdoptionPriority 16 · News

Expected impact by metric